Your browser doesn't support javascript.
loading
Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer's disease.
Alzate, Oscar; Osorio, Cristina; DeKroon, Robert M; Corcimaru, Ana; Gunawardena, Harsha P.
Afiliação
  • Alzate O; Systems Proteomics Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA ; School of Medicine, Universidad Pontificia Bolivariana, Medellin, Colombia ; Current address: 108 Reynolds Medical Building, College of Medicine, Texas A&M Health Science Cent
  • Osorio C; Systems Proteomics Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • DeKroon RM; Systems Proteomics Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Corcimaru A; Systems Proteomics Center, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
  • Gunawardena HP; Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Alzheimers Res Ther ; 6(4): 43, 2014.
Article em En | MEDLINE | ID: mdl-25478016
INTRODUCTION: Alzheimer's disease (AD) is the major cause of dementia among the elderly. Finding blood-based biomarkers for disease diagnosis and prognosis is urgently needed. METHODS: We studied protein distributions in brain tissues, cerebrospinal fluid (CSF), and blood of AD patients by using proteomics and a new proteomic method that we call "2D multiplexed Western blot" (2D mxWd). This method allows us to determine in multiple samples the electrophoretic patterns of protein isoforms with different isoelectric points. RESULTS: Apolipoprotein E (ApoE) displays a unique distribution of electrophoretic isoforms in the presence of AD and also a unique pattern specific to the APOE genotype. CONCLUSIONS: The isoelectric distribution of differentially charged ApoE isoforms was used to determine the presence of AD in a small group of samples. Further studies are needed to validate their use as predictors of disease onset and progression, and as biomarkers for determining the efficacy of therapeutic treatments.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2014 Tipo de documento: Article